# Fouad Azzam

> Fouad Azzam is a Series C investor at EQT Life Sciences backing Health Care and Biotechnology. See 16 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners)
- Total investments: 16
- Last investment: Jul 2025
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/fouadazzam

Fouad Azzam is a Series C investor at EQT Life Sciences focused on Health Care and Biotechnology. Fouad Azzam - General Partner @ EQT Life Sciences

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 50% |
| Biotechnology | 8 | 50% |
| Medical Device | 6 | 38% |
| Medical | 5 | 31% |
| Therapeutics | 4 | 25% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 4 | 25% |
| Series D | 4 | 25% |
| Series B | 3 | 19% |
| Series A | 1 | 6% |
| Funding Round | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neuros Medical | Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $56M | Series D | Jul 09, 2025 |  |
| Shinobi Therapeutics | Shinobi Therapeutics is a biotechnology business that is working on a novel class of immune-evasive iPSC-derived cell treatments. | $51M | Series A | Dec 12, 2023 |  |
| HotSpot Therapeutics | HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts. | $100M | Series C | Nov 29, 2021 |  |
| HotSpot Therapeutics | HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts. | $100M | Series C | Nov 29, 2021 |  |
| Nkarta Therapeutics | Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile. | $114M | Series B | Sep 04, 2019 |  |
| Endotronix | Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worseningheart failure.It was founded in 2007 and is based in Lisle, Illinois. | $70M | Series D | Sep 14, 2018 |  |
| Simplify Medical | Simplify Medical designs, develops, and manufactures cervical artificial discs for use in the spine. It offers an MRI compatible motion preserving artificial cervical disc that is used to treat single level symptomatic cervical disc disease.The company provides its products for skeletally mature patients for reconstruction of the disc at onelevel from C3-C7 following single-level discectomy for intractable radiculopathy, such as arm pain or a neurological deficit.Simplify Medical was founded in 2015 and is based in Mountain View, California. | $23M | Series B | Feb 09, 2018 |  |
| Simplify Medical | Simplify Medical designs, develops, and manufactures cervical artificial discs for use in the spine. It offers an MRI compatible motion preserving artificial cervical disc that is used to treat single level symptomatic cervical disc disease.The company provides its products for skeletally mature patients for reconstruction of the disc at onelevel from C3-C7 following single-level discectomy for intractable radiculopathy, such as arm pain or a neurological deficit.Simplify Medical was founded in 2015 and is based in Mountain View, California. | $21M | Series B | Jul 19, 2017 |  |
| Harvest Automation | Harvest was founded by a seasoned technology executive and a trio of robotics experts. The Company now comprises a diverse, commited team with expertise in sales and marketing, engineering (software, hardware, electrical, mechanical), project management, and business operations. | $11.8M | Series C | Oct 29, 2013 |  |
| Cobalt Technologies | Cobalt Technologies develops technologies that focuses and designed for biofuels. Cobalt is pioneering science that makes possible a new generation of fuels that burn cleaner, are more cost-effective and have a smaller environmental impact. It was founded in 2005 and headquartered in Mountain View, California. | $5M |  | Oct 01, 2012 |  |

10 of 16 investments shown.

## Co-investors
- [Pappas Ventures](https://shizune.co/investors/profile/pappas-ventures) — VC Fund, 4 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 4 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 3 deals together
- [Sectoral Asset Management](https://shizune.co/investors/profile/sectoral-asset-management) — VC Fund, 3 deals together
- [Tekla Capital Management](https://shizune.co/investors/profile/tekla-capital-management) — VC Fund, 3 deals together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 2 deals together

## About EQT Life Sciences

VC Fund · Amsterdam, The Netherlands

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

5 contacts available at EQT Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Christoph Broja | Partner | https://shizune.co/investors/profile/christoph-broja-c9a3 |
| Fouad Azzam | General Partner | https://shizune.co/investors/profile/fouad-azzam |
| Joachim Rothe | General Partner | https://shizune.co/investors/profile/joachim-rothe |
| Daniela Begolo | Managing Director | https://shizune.co/investors/profile/daniela-begolo |
| Ellen Cordo | Chief Finance | https://shizune.co/investors/profile/ellen-cordo |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Fouad Azzam invest in?

Fouad Azzam invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series C and Series D stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Fouad Azzam last invest?

The most recent investment recorded for Fouad Azzam closed in Jul 2025. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co